HBW
ATNM icon

Hazlett, Burt & Watson’s Actinium Pharmaceuticals ATNM Stock Holding History

Hazlett, Burt & Watson’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-200
Closed -$1K – 698
2023
Q4 		$1K Hold
200
– – ﹤0.01% 644
2023
Q3 		$1K Hold
200
– – ﹤0.01% 665
2023
Q2 		$1K Hold
200
– – ﹤0.01% 631
2023
Q1 		$2K Hold
200
– – ﹤0.01% 562
2022
Q4 		$2K Hold
200
– – ﹤0.01% 567
2022
Q3 		$1K Buy
+200
New +$1.24K ﹤0.01% 589

Other funds holding ATNM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Hazlett, Burt & Watson's ATNM Position: Q1 2024 in Review

Hazlett, Burt & Watson sold out of Actinium Pharmaceuticals (ATNM) in Q1 2024, closing a stake of 200 shares — an estimated $1K sold.

Hazlett, Burt & Watson first reported a position in ATNM in Q3 2022 and held it in 6 quarters. The position peaked at $2K in Q1 2023. 67 funds tracked by Wall St. Rank hold ATNM as of Q1 2024.

  • Hazlett, Burt & Watson reported no remaining Actinium Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Hazlett, Burt & Watson sold 200 Actinium Pharmaceuticals shares in Q1 2024, an estimated $1K.
  • Hazlett, Burt & Watson first reported a position in Actinium Pharmaceuticals in Q3 2022 and held it in 6 quarters.
  • Hazlett, Burt & Watson's Actinium Pharmaceuticals position peaked at $2K in Q1 2023.
  • 67 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2024.

Based on Hazlett, Burt & Watson's 13F filing for Q1 2024, filed 29 Apr 2024.